CYTK 240920 50.00C (CYTK240920C50000) Stock Options, News & Quotes

US OptionsDetailed Quotes

CYTK240920C50000

Watchlist

5.95
-0.25-4.03%

15min DelayClose Sep 13 16:00 ET

5.95High4.95Low

Intraday

5D
Daily

News

B.Riley Financial Maintains Cytokinetics(CYTK.US) With Buy Rating, Maintains Target Price $92
Moomoo NewsSep 11 08:31 ET · Ratings
Buy Rating Justified for Cytokinetics Amid Promising Clinical Data and Drug Class Expansion Potential
TipRanksSep 11 07:45 ET · Ratings
Jefferies Maintains Cytokinetics(CYTK.US) With Buy Rating, Maintains Target Price $92
Moomoo NewsSep 10 08:31 ET · Ratings
Cytokinetics Sets Stage For Mid-Stage Study For Heart Failure Drug After Encouraging Data From Phase 1 Study
BenzingaSep 9 13:11 ET
Express News | Cantor Fitzgerald Reiterates Overweight on Cytokinetics
BenzingaSep 9 13:00 ET
Goldman Sachs Maintains Cytokinetics(CYTK.US) With Hold Rating, Maintains Target Price $60
Moomoo NewsSep 9 12:32 ET · Ratings

Comments

Mr Long Term

Aug 13 17:42

Columns Top Calls on Wall Street: Starbucks, Dell, Warner Bros. and More.

Top 5 Upgrades:
Baird upgraded Starbucks $Starbucks (SBUX.US)$ to Outperform from Neutral with a price target of $110, up from $81. The firm sees a more favorable risk/reward on Starbucks shares following the hiring of Brian Niccol as CEO.
Barclays upgraded Dell Technologies $Dell Technologies (DELL.US)$ to Equal Weight from Underweight with an unchanged price target of $97. The firm says much of the artificial intelligence "hype" ...